Home / Guidelines / FDA outlines details of surveys into physical differences in generics

FDA outlines details of surveys into physical differences in generics Posted 26/06/2015

The US Food and Drug Administration (FDA) in a Federal Register notice published on 14 May 2015 has outlined how it will carry out pharmacist and patient surveys into how changes in the physical characteristics of generics pills affect patients’ perceptions.

While generics are required to be pharmaceutically equivalent and bioequivalent to the brand-name drug, generics made by different manufacturers may differ substantially from their brand-name therapeutic equivalents and from each other in their physical appearance, e.g. colour, shape or size of pills.

Since patients may receive generics from different manufacturers when refilling their prescriptions, FDA is concerned that changes in the appearance of their drugs may cause ‘patient confusion and concerns about the safety and effectiveness’ of the generics.

The agency is therefore carrying out a national survey of pharmacists about their experiences with dispensing generics pills that differ in appearance from previous refills of the same medication and dosage level, e.g. when pharmacies switch generic suppliers.

FDA will send out 2,161 questionnaires to pharmacists in order to obtain the 1,000 responses required for adequate statistical power. The pharmacists will be asked about the frequency with which their pharmacy changes suppliers that lead to variations in the appearance of the generic drugs that they dispense, as well as strategies they use with patients to address the transition to pills that have a different appearance, e.g. alert stickers on pill bottles, verbal warnings and other strategies. They will also be asked about patient responses to changes in pill appearance, including what types of appearance changes seem to affect patients most often (shape/colour/size), how often patients report confusion about pill appearance, and how often patients ultimately refuse to accept the new product.

FDA will also survey patients using two different methodologies. The first is a telephone survey of patients who are 50 years and older and who take one or more generics for at least one of the following chronic conditions: epilepsy, diabetes, hypertension, hyperlipidaemia, depression and HIV.

For the second patient survey, patients will be selected from a proprietary research database of commercially insured patients containing medical and pharmacy claims linked to health insurance enrolment information. A nationally representative sample of patients with at least one chronic condition and who experienced a change in physical appearance of a generic pill will be identified by the research team using medical and pharmacy claims data.

Both patient surveys will consist of questions covering topics similar to those asked in the survey of pharmacists and is intended to provide answers to the same topic areas from patients’ perspectives. As before, topic areas will include beliefs about generic drugs, outcomes related to changes in generics pill appearance, and strategies used by pharmacists or doctors to alert patients to the possibility of changes in appearance.

The results from the surveys are intended to provide additional information that may help guide regulatory policy or pharmacy business practices. FDA published its draft guidance for industry on the size, shape and other physical attributes of generics for comment in December 2013 [1].

Related article
FDA to carry out survey into affect of generics shape, colour, size

Reference
1. GaBI Online - Generics and Biosimilars Initiative. US guidelines for generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Jun 26]. Available from: www.gabionline.net/Guidelines/US-guidelines-for-generics

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.

Source: Federal Register, FDA

Comments (0)